Sarepta Therapeutics

Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy
Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy
Endpoints
Sarepta Therapeutics
Doug Ingram
executive pay
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Stat
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
golodirsen
Exondys 51
Flag link:
Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event
Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event
Endpoints
Sarepta Therapeutics
golodirsen
Duchenne Muscular Dystrophy
UK
Flag link:
Sarepta is making a bold bet on genetic medicine
Sarepta is making a bold bet on genetic medicine
Marketwatch
Sarepta Therapeutics
gene therapy
gene editing
genetic medicine
Flag link:
What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll
What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll
Endpoints
Sarepta Therapeutics
Ed Kaye
Stoke Therapeutics
Flag link:
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
BioPharma Dive
Anthem
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD
Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD
Endpoints
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
golodirsen
Flag link:
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
Endpoints
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
These 3 Biotechs Just Crushed Analyst Expectations
These 3 Biotechs Just Crushed Analyst Expectations
Motley Fool
biotech
earnings
Sarepta Therapeutics
Biogen
Gilead Sciences
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Endpoints
Allergan
Sarepta Therapeutics
Doug Ingram
Flag link:
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Endpoints
Sarepta Therapeutics
Genethon
Duchenne Muscular Dystrophy
gene therapy
China
Pluristem
Flag link:
After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
Endpoints
Sarepta Therapeutics
Chris Garabedian
Xontogeny
startups
Flag link:
How Much Would Sarepta Therapeutics Fetch in a Buyout?
How Much Would Sarepta Therapeutics Fetch in a Buyout?
Motley Fool
Sarepta Therapeutics
M&A
Flag link:
Sarepta Therapeutics May Attract Activist Attention
Sarepta Therapeutics May Attract Activist Attention
TheStreet.com
Sarepta Therapeutics
activists
Flag link:
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
TheStreet.com
Sarepta Therapeutics
Sanofi
M&A
Pharma CEOs
Ed Kaye
Flag link:
Biotech Movers: Sarepta, Paratek, PDL BioPharma
Biotech Movers: Sarepta, Paratek, PDL BioPharma
TheStreet.com
Sarepta Therapeutics
Exondys 5
Paratek
omadacycline
PDL Biopharma
patents
Merck
Keytruda
Flag link:
Sarepta chief hands over CMO role to former Regeneron exec
Sarepta chief hands over CMO role to former Regeneron exec
Bizjournals.com
Sarepta Therapeutics
Regeneron
CMOs
Flag link:

Pages